SIRT3 and Parkinson disease: In this regard, it has been shown that the use of the SIRT1 agonist resveratrol and the SIRT3 agonist honokiol can improve the disease phenotype in PD mouse models [205,206,207,208,209], suggesting that promoting DNA repair is a potential target for PD therapy.